Cardiol Therapeutics (TSX:CRDL) Other Stockholders Equity : C$-0.00 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics Other Stockholders Equity?

Cardiol Therapeutics's Other Stockholders Equity for the quarter that ended in Sep. 2024 was C$-0.00 Mil.

Cardiol Therapeutics's quarterly Other Stockholders Equity declined from Mar. 2024 (C$3.52 Mil) to Jun. 2024 (C$-0.00 Mil) but then increased from Jun. 2024 (C$-0.00 Mil) to Sep. 2024 (C$-0.00 Mil).

Cardiol Therapeutics's annual Other Stockholders Equity declined from Dec. 2021 (C$4.18 Mil) to Dec. 2022 (C$3.52 Mil) and declined from Dec. 2022 (C$3.52 Mil) to Dec. 2023 (C$3.52 Mil).

Cardiol Therapeutics Other Stockholders Equity Historical Data

The historical data trend for Cardiol Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics Other Stockholders Equity Chart

Cardiol Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

1.73

4.46

4.18

3.52

Cardiol Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Stockholders Equity	Get a 7-Day Free Trial															3.52	3.52	3.52	-	-

Cardiol Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Cardiol Therapeutics Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CRDL:USA CT9:Germany

Address

2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5

Website

https://www.cardiolrx.com

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Executives

Guillermo Torre	Senior Officer
Colin George Stott	Director
Deborah Brown	Director
Peter Pekos	Director
Iain Chalmers	Director
David Elsley	Director, Senior Officer
Eldon Smith	Director
Christopher James Waddick	Director, Senior Officer